Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered...
-- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDASHANGHAI, China, Aug. 25,...
Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab...
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock...
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA – – First...
Patient denied testing for weeks due to risk of physician infection & non-MSM status Amerimmune Long COVID Panel and Provista...
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter...
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three...
- Neuroendocrine Prostate Cancer is Growing Unmet Medical Need - NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences...
IRVINE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to...
Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from...
Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece. In addition to these...
33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent...
Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical studyREHOVOT, Israel and WILMINGTON, Del., Aug....
Patient relationship management and contact center technology enables Science 37 to achieve significantly greater patient engagementRESEARCH TRIANGLE PARK, N.C., Aug....
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced...
REYKJAVIK, Iceland and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in...
PRESS RELEASE: 24 August 2022, 07:00 CEST Biocartis Obtains ISO 27001 Certification for Information Security Management Mechelen, Belgium, 24 August 2022 –...
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR in advanced...
Initial focus of five-year collaboration will be on potentially best-in-class ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, which together comprise...